Biomimetic Biomembrane Encapsulation and Targeted Delivery of a Nitric Oxide Release Platform for Therapy of Parkinson's Disease

ACS Biomater Sci Eng. 2023 May 8;9(5):2545-2557. doi: 10.1021/acsbiomaterials.3c00146. Epub 2023 Apr 11.

Abstract

The existence of the blood-brain barrier (BBB) and the complex inflammatory environment in the brain are two major obstacles in the treatment of Parkinson's disease (PD). As a target group, we modified the red blood cell membrane (RBCM) on the surface of upconversion nanoparticles (UCNPs) in this study to effectively target the brain. Mesoporous silicon, coated with UCNPs (UCM), was loaded with S-nitrosoglutathione (GSNO) as the nitric oxide (NO) donor. Then, UCNPs were excited to emit green light (540 nm) by 980 nm near-infrared (NIR). In addition, it produced a light-responsive anti-inflammatory effect by promoting the release of NO from GSNO and lowering the brain's level of proinflammatory factors. A series of experiments demonstrated that this strategy could effectively mitigate the inflammatory response damage of neurons in the brain.

Keywords: 980 nm NIR; Parkinson’s disease; nitric oxide; upconversion.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomimetics
  • Humans
  • Nanoparticles*
  • Nitric Oxide
  • Nitric Oxide Donors / pharmacology
  • Nitric Oxide Donors / therapeutic use
  • Parkinson Disease* / drug therapy
  • Photosensitizing Agents

Substances

  • Photosensitizing Agents
  • Nitric Oxide
  • Nitric Oxide Donors